Pfizer reports first-quarter 2014 results
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) reported financial results for first-quarter 2014. At the beginning of fiscal year 2014, the company began managing its commercial operations through a new global commercial structure consisting of three operating segments: the Global Innovative Pharmaceutical segment (GIP); the Global Vaccines, Oncology and Consumer Healthcare segment (VOC); and the Global Established Pharmaceutical segment (GEP).
AstraZeneca Board rejects Pfizer proposal
- Details
- Category: AstraZeneca
The Board of AstraZeneca PLC has met and considered the letter from Pfizer Inc. The board said it has "no hesitation in rejecting the proposal", which it believed "inadequate, substantially undervalue" the company.
Pfizer sends letter to Rt Hon David Cameron MP regarding commitments if proposed combination with AstraZeneca is completed
- Details
- Category: Pfizer
Pfizer Chairman and Chief Executive Officer, Ian Read, today sent the following letter to the Rt Hon David Cameron MP, with respect to Pfizer's commitment to the U.K. and its life sciences agenda following the company’s proposal made to AstraZeneca on May 2, 2014.
Bayer: Very successful start to 2014
- Details
- Category: Bayer
Sales of the Bayer Group advanced by 2.8 percent in the first quarter of 2014 to EUR 10,555 million (Q1 2013: EUR 10,266 million). Adjusted for currency and portfolio effects (Fx & portfolio adj.), business expanded by 8.4 percent. EBIT rose by 18.4 percent to EUR 2,096 million (Q1 2013: EUR 1,771 million) after net special items of plus EUR 7 million (Q1 2013: minus EUR 45 million). EBIT before special items increased by 15.0 percent to EUR 2,089 million (Q1 2013: EUR 1,816 million).
Pfizer Confirms prior discussions with AstraZeneca
- Details
- Category: Pfizer
Pfizer Inc. confirms that it previously submitted a preliminary, non-binding indication of interest to the board of directors of AstraZeneca in January 2014 regarding a possible merger transaction. After limited high-level discussions, AstraZeneca declined to pursue negotiations.
Novartis delivered solid sales and profit growth in the first quarter of 2014
- Details
- Category: Novartis
Subsequent to the quarter end, Novartis announced that it had reached definitive agreements with GlaxoSmithKline plc (GSK) and Eli Lilly and Company (Lilly) on a set of transactions. In an inter-conditional transaction with GSK: (1) Novartis agreed to acquire GSK oncology products and to become GSK's preferred commercialization partner for its oncology pipeline for a USD 14.5 billion payment and up to USD 1.5 billion contingent on a development milestone;
Bristol-Myers Squibb ranks first on 2014 Best Corporate Citizens List
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) has been ranked No. 1 on Corporate Responsibility magazine's 2014 list of the 100 Best Corporate Citizens, a leading benchmark for socially responsible investors and other stakeholders. Bristol-Myers Squibb is the only company to achieve the No. 1 ranking three times, including 2009 and 2012, and has ranked among the top 10 each of the last six years.
More Pharma News ...
- Novartis announces portfolio transformation
- Abbott reports first-quarter 2014 results
- Roche with good start in 2014
- Abbott completes enrollment of Absorb™ randomized clinical trials in the United States, Japan and China
- Novartis and Malaria No More provide two million antimalarial treatments to children in Zambia
- Merck Serono enters into research agreement with Pfizer and Broad Institute
- Bayer HealthCare to significantly increase production capacity in China